Share

    


Home / Search Results

Search Results

You searched for:

The Centers for Medicare & Medicaid Services and the American Medical Association's (AMA's) finalized coding updates for calendar year 2022.
If enacted, patients with cancer across the country will benefit from increased access and new fiscal protections, including universal paid family leave.
The Medicare Physician Fee Schedule (MPFS) for calendar year 2022.
On Aug. 4, the Centers for Medicare & Medicaid Services (CMS) released its 2021 Hospital Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (PFS) proposed rules.
The Centers for Medicare and Medicaid Services (CMS) released the final Medicare payment rules for calendar year (CY) 2020 in tandem this year on Nov. 1, 2019.
On Sept. 27, ACCC provided comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s proposed CY 2020 Outpatient Prospective Payment System (OPPS) and Physician Fee Schedule (PFS) rules.
Calendar year (CY) 2020 begins the transition in the Medicare physician fee schedule (PFS) payment system away from fee-for-service reimbursement, which is affected by the changing conversion factor, to a payment system that is set with potential changes related to budget neutrality.
Drug pricing reform and a thorough analysis of healthcare spending have been the focus of healthcare leadership across the country since early 2018.
November 26, 2018 The Honorable Gus Bilirakis U.S. House of Representatives 2112 Rayburn House Office Building Washington, DC 20515 The Honorable Ben Ray Lujan U.S. House of Representatives 2231 Rayburn House Office Building Washington, DC 20515 Dear Representative Bilirakis and Representative Lujan, On behalf of the undersigned organizations, representing …
In September 2018, the Association of Community Cancer Centers (ACCC) submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to both the 2019 Physician Fee Schedule (PFS) and Hospital Outpatient Prospective Payment System (OPPS) proposed rules. The arrival of autumn signals seasonal changes, but one constant is the policy implications of the proposed Medicare payment rules …
Effective Oct. 1, 2018, the Centers for Medicare & Medicaid Services (CMS) and the Centers for Disease Control and Prevention will add 279 new codes, revise 143 existing codes, and deactivate 51 codes in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) classification.
Although the Trump administration has maintained a steady drumbeat on pharmaceutical pricing in recent months, promising lower costs for patients and less spending for the government, it wasn’t until late summer that we started to see what this White House had in mind.
Secretary Alex Azar has expressed strong interest in revitalizing Medicare’s Competitive Acquisition Program (CAP) and introducing negotiation into Part B drug pricing.
All eyes are on Congress in recent months with Affordable Care Act repeal and tax reform, but the real action—and consequential reimbursement decisions for ACCC cancer programs—is happening on the regulatory side.
While the 340B Program has grown, and reform has been widely debated by policymakers over the past decade, CMS’ rule proposes to fundamentally alter the program (notably a program that is not within CMS’ purview).
Summer headlines have been dominated by congressional efforts to repeal and replace portions of the Affordable Care Act (ACA) and find a politically palatable path forward to shoring up the nongroup insurance market.
In early March, the Centers for Medicare and Medicaid Services (CMS) issued a proposal to implement a national demonstration program that would fundamentally change the way Medicare pays physicians and hospitals for Part B drugs.